Reduction of particle-induced osteolysis by interleukin-6 involves anti-inflammatory effect and inhibition of early osteoclast precursor differentiation

Bone

Volumn 45, Issue 4, 2009, Pages 661-668

  Darowish, Michael ^a   Rahman, Ra'Kerry ^a   Li, Ping ^a   Bukata, Susan V ^a   Gelinas, Jill ^a   Huang, Willis ^a   Flick, Lisa M ^a   Schwarz, Edward M ^a   O'Keefe, Regis J ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

IL 6; Inflammatory bone loss; Macrophages; Osteoclastogenesis; TNF

Indexed keywords

COLONY STIMULATING FACTOR 1; INTERLEUKIN 6; TITANIUM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CELL SURFACE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; SPLEEN CELL; STEM CELL;

ANIMALS; ANTIGENS, CD11B; CELL DIFFERENTIATION; INFLAMMATION; INTERLEUKIN-6; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; OSTEOCLASTS; OSTEOGENESIS; OSTEOLYSIS; SPLEEN; STEM CELLS; TITANIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68849099862     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.06.004     Document Type: Article

References (52)

1. Margevicius K.J., Bauer T.W., McMahon J.T., Brown S.A., and Merritt K. Isolation and characterization of debris in membranes around total joint prostheses. J. Bone Joint Surg. Am. 76 (1994) 1664-1675
2. Chiba J., Schwendeman L.J., Booth Jr. R.E., Crossett L.S., and Rubash H.E. A biochemical, histologic, and immunohistologic analysis of membranes obtained from failed cemented and cementless total knee arthroplasty. Clin. Orthop. Relat. Res. (1994) 114-124
3. Haynes D.R., Crotti T.N., Potter A.E., Loric M., Atkins G.J., Howie D.W., et al. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J. Bone Joint Surg. Br. 83 (2001) 902-911
4. O'Gradaigh D., Ireland D., Bord S., and Compston J.E. Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. Ann. Rheum. Dis. 63 (2004) 354-359
5. Arai F., Miyamoto T., Ohneda O., Inada T., Sudo T., Brasel K., et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J. Exp. Med. 190 (1999) 1741-1754
6. Yao Z., Li P., Zhang Q., Schwarz E.M., Keng P., Arbini A., et al. Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J. Biol. Chem. 281 (2006) 11846-11855
7. Li P., Schwarz E.M., O'Keefe R.J., Ma L., Boyce B.F., and Xing L. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J. Bone Miner. Res. 19 (2004) 207-213
8. Li P., Schwarz E.M., O'Keefe R.J., Ma L., Looney R.J., Ritchlin C.T., et al. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11b(high) osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum. 50 (2004) 265-276
9. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
10. Cenci S., Weitzmann M.N., Roggia C., Namba N., Novack D., Woodring J., et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J. Clin. Invest. 106 (2000) 1229-1237
11. Collin-Osdoby P., Rothe L., Anderson F., Nelson M., Maloney W., and Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol. Chem. 276 (2001) 20659-20672
12. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., and Teitelbaum S.L. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106 (2000) 1481-1488
13. Azuma Y., Kaji K., Katogi R., Takeshita S., and Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275 (2000) 4858-4864
14. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191 (2000) 275-286
15. Sabokbar A., Kudo O., and Athanasou N.A. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. J. Orthop. Res. 21 (2003) 73-80
16. Konttinen Y.T., Xu J.W., Waris E., Li T.F., Gomez-Barrena E., Nordsletten L., et al. Interleukin-6 in aseptic loosening of total hip replacement prostheses. Clin. Exp. Rheumatol. 20 (2002) 485-490
17. Bukata S.V., Gelinas J., Wei X., Rosier R.N., Puzas J.E., Zhang X., et al. PGE2 and IL-6 production by fibroblasts in response to titanium wear debris particles is mediated through a Cox-2 dependent pathway. J. Orthop. Res. 22 (2004) 6-12
18. Kim K.J., Hijikata H., Itoh T., and Kumegawa M. Joint fluid from patients with failed total hip arthroplasty stimulates pit formation by mouse osteoclasts on dentin slices. J. Biomed. Mater. Res. 43 (1998) 234-240
19. Kotake S., Sato K., Kim K.J., Takahashi N., Udagawa N., Nakamura I., et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11 (1996) 88-95
20. Aderka D., Le J.M., and Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J. Immunol. 143 (1989) 3517-3523
21. Balto K., Sasaki H., and Stashenko P. Interleukin-6 deficiency increases inflammatory bone destruction. Infect. Immun. 69 (2001) 744-750
22. Yoshitake F., Itoh S., Narita H., Ishihara K., and Ebisu S. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J. Biol. Chem. 283 (2008) 11535-11540
23. Benihoud K., Salone B., Esselin S., Opolon P., Poli V., Di Giovine M., et al. The role of IL-6 in the inflammatory and humoral response to adenoviral vectors. J. Gene Med. 2 (2000) 194-203
24. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368 (1994) 339-342
25. Poli V., Balena R., Fattori E., Markatos A., Yamamoto M., Tanaka H., et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13 (1994) 1189-1196
26. Schwarz E.M., Benz E.B., Lu A.P., Goater J.J., Mollano A.V., Rosier R.N., et al. Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis. J. Orthop. Res. 18 (2000) 849-855
27. Keffer J., Probert L., Cazlaris H., Georgopoulos S., Kaslaris E., Kioussis D., et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10 (1991) 4025-4031
28. Huang W., O'Keefe R.J., and Schwarz E.M. Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation. Arthritis Res. Ther. 5 (2003) R49-R59
29. Li P., Sanz I., O'Keefe R.J., and Schwarz E.M. NF-kappa B regulates VCAM-1 expression on fibroblast-like synoviocytes. J. Immunol. 164 (2000) 5990-5997
30. Soloviev A., Schwarz E.M., Kuprash D.V., Nedospasov S.A., Puzas J.E., Rosier R.N., et al. The role of p105 protein in NFkappaB activation in ANA-1 murine macrophages following stimulation with titanium particles. J. Orthop. Res. 20 (2002) 714-722
31. Lam J., Abu-Amer Y., Nelson C.A., Fremont D.H., Ross F.P., and Teitelbaum S.L. Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis. Ann. Rheum. Dis. 61 Suppl. 2 (2002) ii82-ii83
32. Misawa E., Sakurai T., Yamada M., Tamura Y., and Motoyoshi K. Administration of macrophage colony-stimulating factor mobilized both CD11b+CD11c+ cells and NK1.1+ cells into peripheral blood. Int. Immunopharmacol. 4 (2004) 791-803
33. Black K., Garrett I.R., and Mundy G.R. Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinology 128 (1991) 2657-2659
34. Sandhu J.S., Gorczynski R.M., Waddell J., Nguyen H., Squires J., Boynton E.L., et al. Effect of interleukin-6 secreted by engineered human stromal cells on osteoclasts in human bone. Bone 24 (1999) 217-227
35. Palmqvist P., Persson E., Conaway H.H., and Lerner U.H. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J. Immunol. 169 (2002) 3353-3362
36. Kitamura H., Kawata H., Takahashi F., Higuchi Y., Furuichi T., and Ohkawa H. Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow. Am. J. Pathol. 147 (1995) 1682-1692
37. Barton B.E., and Mayer R. IL 3 and IL 6 do not induce bone resorption in vitro. Cytokine 2 (1990) 217-220
38. Holt I., Davie M.W., Braidman I.P., and Marshall M.J. Interleukin-6 does not mediate the stimulation by prostaglandin E2, parathyroid hormone, or 1,25 dihydroxyvitamin D3 of osteoclast differentiation and bone resorption in neonatal mouse parietal bones. Calcif. Tissue Int. 55 (1994) 114-119
39. Duplomb L., Baud'huin M., Charrier C., Berreur M., Trichet V., Blanchard F., et al. Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. Endocrinology 149 (2008) 3688-3697
40. Nishimoto N., Hashimoto J., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66 (2007) 1162-1167
41. Smolen J.S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371 (2008) 987-997
42. Kato A., Matsuo S., Takai H., Uchiyama Y., Mihara M., and Suzuki M. Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model. Exp. Mol. Pathol. 84 (2008) 262-270
43. Kamimura D., Ishihara K., and Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 149 (2003) 1-38
44. Huang W., Drissi M.H., O'Keefe R.J., and Schwarz E.M. A rapid multiparameter approach to study factors that regulate osteoclastogenesis: demonstration of the combinatorial dominant effects of TNF-alpha and TGF-ss in RANKL-mediated osteoclastogenesis. Calcif. Tissue Int. 73 (2003) 584-593
45. van de Loo F.A., Kuiper S., van Enckevort F.H., Arntz O.J., and van den Berg W.B. Interleukin-6 reduces cartilage destruction during experimental arthritis. A study in interleukin-6-deficient mice. Am. J. Pathol. 151 (1997) 177-191
46. Shin H.I., Divieti P., Sims N.A., Kobayashi T., Miao D., Karaplis A.C., et al. Gp130-mediated signaling is necessary for normal osteoblastic function in vivo and in vitro. Endocrinology 145 (2004) 1376-1385
47. Fattori E., Cappelletti M., Costa P., Sellitto C., Cantoni L., Carelli M., et al. Defective inflammatory response in interleukin 6-deficient mice. J. Exp. Med. 180 (1994) 1243-1250
48. Ulich T.R., Guo K.Z., Remick D., del Castillo J., and Yin S.M. Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6. J. Immunol. 146 (1991) 2316-2323
49. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J. Clin. Invest. 101 (1998) 311-320
50. Moreno J.L., Kaczmarek M., Keegan A.D., and Tondravi M. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. Blood 102 (2003) 1078-1086
51. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374 (2003) 1-20
52. Rakshit D.S., Ly K., Sengupta T.K., Nestor B.J., Sculco T.P., Ivashkiv L.B., et al. Wear debris inhibition of anti-osteoclastogenic signaling by interleukin-6 and interferon-gamma. Mechanistic insights and implications for periprosthetic osteolysis. J. Bone Joint. Surg. Am. 88 (2006) 788-799